Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-14
1997-11-18
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
056888015
ABSTRACT:
A pharmaceutical composition comprising a biodegradable and biocompatible composition comprising a 1,2 benzazole within a polymeric matrix. The 1,2 benzazole composition, pharmaceutically acceptable acid addition salts thereof, are potent antagonists of a series of neurotransmitters, particularly serotonin and dopamine. A method of inhibiting both serotonergic overactivity and dopaminergic overstimulation in animals is provided by administration of a biodegradable and biocompatible microparticle composition comprising a 1,2 benzazole or a pharmaceutically acceptable acid addition salt thereof. A method of treating warm blooded animals suffering from psychotic disorders, and a method of preparing the biodegradable and biocompatible composition are also described.
REFERENCES:
patent: 3197180 (1965-07-01), Bates et al.
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3773919 (1973-11-01), Albert et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3923288 (1975-12-01), King et al.
patent: 3960757 (1976-06-01), Morishita et al.
patent: 4034965 (1977-07-01), King et al.
patent: 4111402 (1978-09-01), Barbini et al.
patent: 4128641 (1978-12-01), Itil et al.
patent: 4201482 (1980-05-01), Imhauser et al.
patent: 4208136 (1980-06-01), King et al.
patent: 4329331 (1982-05-01), Kallick et al.
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4337261 (1982-06-01), Shutske et al.
patent: 4342870 (1982-08-01), Kennis et al.
patent: 4352811 (1982-10-01), Strupczewski
patent: 4389330 (1983-06-01), Tice et al.
patent: 4443451 (1984-04-01), Kennis et al.
patent: 4458076 (1984-07-01), Strupczewski
patent: 4485107 (1984-11-01), Kennis et al.
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4511258 (1985-04-01), Federighi et al.
patent: 4529727 (1985-07-01), Kennis et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4614440 (1986-09-01), King et al.
patent: 4616937 (1986-10-01), King et al.
patent: 4643584 (1987-02-01), Allocca et al.
patent: 4665075 (1987-05-01), Vandenberk et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4677191 (1987-06-01), Tankana et al.
patent: 4683288 (1987-07-01), Tankana et al.
patent: 4689330 (1987-08-01), Janssens et al.
patent: 4696258 (1987-09-01), Magrath et al.
patent: 4731205 (1988-03-01), McNulty et al.
patent: 4737500 (1988-04-01), Sorg et al.
patent: 4753535 (1988-06-01), King et al.
patent: 4765204 (1988-08-01), Buchholz et al.
patent: 4793713 (1988-12-01), King et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4808007 (1989-02-01), King et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4883666 (1989-11-01), Sabel et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4936689 (1990-06-01), Federighi et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5158952 (1992-10-01), Janssen et al.
Baker, J.R., "Motionless Mixers Stir Up New Uses", Chemical Engineering Progress:32-38 (Jun. 1991).
Borison, R.L. et al., "Clinical Overview of Risperidone", in: Meltzer, H.Y. (ed.), Novel Antipsychotic Drugs, Raven Press, Ltd., New York:233-239 (1992).
Chemineer, "Kenics Static Mixers", Bulletin 800:1-11 (1986).
Chouinard, G. et al., "A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperiodol in the Treatment of Chronic Schizophrenic Patients", J. Clin. Psychopharm. 13(1):25-40 (1993).
Glazer, W.M. et al., "Depot Neuroleptic Therapy: An Underutilized Treatment Option", J. Clin. Psychiatry 53(12):426-433 (Dec., 1992).
Heinrich, K. et al., "Experimental Comparison of the Efficacy and Compatibility of Risperidone and Clozapine in Acute Schizophrenia" in: Kane, J.M. (ed.), Risperidone: Major Progress in Antipsychotic Treatment. Oxford Clinical Communications, Oxford:37-39 (1991).
Janssen and Niemegeers, "Chemistry and Pharmacology of Compounds Related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone", Arzneim.-Forsch. (Drug Res.) 12:765-767 (1959).
Janssen, P.A.J. et al., "Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquilizers) from Animal Data?", Arzneim. Forsch. (Drug Res.) 10:1196-1206 (1965).
Janssen, P.A.J. et al., "Pharmacology of Risperidone (R 64 766), a New Antipsychotic with Serotonin-S.sub.2 and Dopamine-D.sub.2 Antagonistic Properties", J. Pharmacol. Exp. Ther. 244(2):685-693 (1988).
Koch Engineering Company, Inc., "Static Mixing Technology", Article:1-15 (1991).
Koch Engineering Company, Inc., "All Mixing Problems Are Not Alike", 1 page, Product Brochure.
Koflo Corporation, "Static In-Line Mixers", 4 pages, Product Brochure.
Komax Systems, Inc., "Triple Action Static Mixers", 2 pages, Product Brochure.
Leysen, J.E. et al., "In vitro Receptor Binding and Neurotransmitter Uptake Inhibition Profile of R 64 766, R 76 477, R 78 543 and R 78 544", Janssen Research Foundation, Beerse, Belgium, N79120, Preclinical Research Report R 64 766/28, 11 pages (Jan., 1991).
Leysen, J.E. et al., "Biochemical Profile of Risperidone, a New Antipsychotic", J. Pharmacol. Exp. Ther. 247(2):661-670 (1988).
Maulding, H.V. et al., "Biodegradable Microcapsules: Acceleration of Polymeric Excipient Hydrolytic Rate by Incorporation of a Basic Medicament", J. Controlled Release 3:103-117 (1986).
Megens and Niemegeers, "Comparative Pharmacology of Risperidone, its Major Metabolite R 76 477.sup.(+/-) and the Corresponding Enantiomers R 78 543.sup.(+) and R 78 544.sup.(+) in Rats and Dogs", Janssen Research Foundation, Beerse, Belgium, N74694, Preclinical Research Report R 64 766/23, 12 pages (Jun., 1990).
Mergens and Awouters, "In vivo Pharmacological Profile of 9-hydroxyrisperidone, the Major Metabolite of the Novel Antipsychotic Risperidone: Comparison with Risperidone and Haloperidol", Janssen Research Foundation, Beerse, Belgium, N 96295, Preclinical Research Report R 64 766/R76 477, 26 pages (May 1993).
Mertens, C., "Long-term Treatment of Chronic Schizophrenic Patients with Risperidone", in: Kane, J.M. (ed.), Risperidone: Major Progress in Antipsychotic Treatment, Oxford Clinical Communications, Oxford:44-48 (1991).
Mutsakis et al., "Advances in Static Mixing Technology", Chemical Engineering Progress:42-48 (Jul. 1986).
Niemegeers and Janssen, "A Systematic Study of the Pharmacological Activities of Dopamine Antagonists", in: Life Science 24(24):2201-2216, Pergamon Press, Ltd. (1979).
Niemegeers et al., "Antiemetic Specificity of Dopamine Antagonists", Psychopharmacology 78:210-213 (1982).
Streiff, F., "In-line Dispersion and Mass Transfer using Static Mixing Equipment", Sulzer Technical Review 3:108-114 (1977).
Atkins Thomas J.
Mesens Jean
Rickey Michael E.
Alkermes Controlled Therapeutics Inc. II
Dees Jos,e G.
Janssen Pharmaceutica
Oswecki Jane C.
LandOfFree
Method of inhibiting neurotransmitter activity using microencaps does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting neurotransmitter activity using microencaps, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting neurotransmitter activity using microencaps will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1565876